Clinical Warburg effect in lymphoma patients admitted to intensive care unit.
Intensive care unit
Lactate
Lymphoma
Warburg effect
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
05 Oct 2023
05 Oct 2023
Historique:
received:
20
07
2023
accepted:
20
09
2023
medline:
5
10
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
epublish
Résumé
The Warburg effect, characterized by elevated lactate levels without tissue hypoxia or shock, has been described in patients with aggressive lymphoproliferative malignancies. However, the clinical characteristics and long-term outcomes in this population remain poorly understood. We retrospectively analyzed 135 patients with aggressive lymphoproliferative malignancies admitted to the ICU between January 2017 and December 2022. Patients were classified into three groups: Clinical Warburg Effect (CWE), No Warburg with High Lactate level (NW-HL), and No Warburg with Normal Lactate level (NW-NL). Clinical characteristics and outcomes were compared between the groups and factors associated with 1-year mortality and CWE were identified using multivariable analyses. Of the 135 patients, 46 (34%) had a CWE. This group had a higher proportion of Burkitt and T cell lymphomas, greater tumor burden, and more frequent bone and cerebral involvement than the other groups. At 1 year, 72 patients (53%) died, with significantly higher mortality in the CWE and NW-HL groups (70% each) than in the NW-NL group (38%). Factors independently associated with 1-year mortality were age [HR = 1.02 CI 95% (1.00-1.04)], total SOFA score at admission [HR = 1.19 CI 95% (1.12-1.25)], and CWE [HR = 3.87 CI 95% (2.13-7.02)]. The main factors associated with the CWE were tumor lysis syndrome [OR = 2.84 CI 95% (1.14-7.42)], bone involvement of the underlying malignancy [OR = 3.58 CI 95% (1.02-12.91)], the total SOFA score at admission [OR = 0.81 CI 95% (0.69-0.91)] and hypoglycemia at admission [OR = 14.90 CI 95% (5.42-47.18)]. CWE is associated with a higher tumor burden and increased 1-year mortality compared to patients without this condition. Our findings underscore the importance of recognizing patients with CWE as a high-risk cohort, as their outcomes closely resemble those of individuals with lymphoma and shock, despite not requiring advanced organ support. Clinicians should recognize the urgency of managing these patients and consider early intervention to improve their prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
The Warburg effect, characterized by elevated lactate levels without tissue hypoxia or shock, has been described in patients with aggressive lymphoproliferative malignancies. However, the clinical characteristics and long-term outcomes in this population remain poorly understood.
METHODS
METHODS
We retrospectively analyzed 135 patients with aggressive lymphoproliferative malignancies admitted to the ICU between January 2017 and December 2022. Patients were classified into three groups: Clinical Warburg Effect (CWE), No Warburg with High Lactate level (NW-HL), and No Warburg with Normal Lactate level (NW-NL). Clinical characteristics and outcomes were compared between the groups and factors associated with 1-year mortality and CWE were identified using multivariable analyses.
RESULTS
RESULTS
Of the 135 patients, 46 (34%) had a CWE. This group had a higher proportion of Burkitt and T cell lymphomas, greater tumor burden, and more frequent bone and cerebral involvement than the other groups. At 1 year, 72 patients (53%) died, with significantly higher mortality in the CWE and NW-HL groups (70% each) than in the NW-NL group (38%). Factors independently associated with 1-year mortality were age [HR = 1.02 CI 95% (1.00-1.04)], total SOFA score at admission [HR = 1.19 CI 95% (1.12-1.25)], and CWE [HR = 3.87 CI 95% (2.13-7.02)]. The main factors associated with the CWE were tumor lysis syndrome [OR = 2.84 CI 95% (1.14-7.42)], bone involvement of the underlying malignancy [OR = 3.58 CI 95% (1.02-12.91)], the total SOFA score at admission [OR = 0.81 CI 95% (0.69-0.91)] and hypoglycemia at admission [OR = 14.90 CI 95% (5.42-47.18)].
CONCLUSION
CONCLUSIONS
CWE is associated with a higher tumor burden and increased 1-year mortality compared to patients without this condition. Our findings underscore the importance of recognizing patients with CWE as a high-risk cohort, as their outcomes closely resemble those of individuals with lymphoma and shock, despite not requiring advanced organ support. Clinicians should recognize the urgency of managing these patients and consider early intervention to improve their prognosis.
Identifiants
pubmed: 37796407
doi: 10.1186/s13613-023-01192-z
pii: 10.1186/s13613-023-01192-z
pmc: PMC10555986
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97Informations de copyright
© 2023. La Société de Réanimation de Langue Francaise = The French Society of Intensive Care (SRLF).
Références
Warburg O, Minami S. Versuche an überlebendem carcinom-gewebe. Klin Wochenschr. 1923;2:776–7.
Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
pubmed: 13298683
Chance B. Dynamics of respiratory pigments of ascites tumor cells. Trans N Y Acad Sci. 1953;16:74–5.
pubmed: 13169227
Chance B, Hess B. On the control of metabolism in ascites tumor cell suspensions. Ann N Y Acad Sci. 1956;63:1008–16.
pubmed: 13314450
Weinhouse S. On respiratory impairment in cancer cells. Science. 1956;124:267–9.
pubmed: 13351638
Weinhouse S. The Warburg hypothesis fifty years later. Z Krebsforsch. 1976;87:115–26.
Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol. 2021;599:1745–57.
pubmed: 33347611
Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325–37.
pubmed: 21508971
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
pubmed: 19460998
pmcid: 2849637
Abdel-Haleem AM, Lewis NE, Jamshidi N, Mineta K, Gao X, Gojobori T. The emerging facets of non-cancerous Warburg effect. Front Endocrinol. 2017;8:279.
Cohen RD. Clinical and biochemical aspects of lactic acidosis. Oxford: Blackwell Scientific; 1976.
Cohen RD, Woods HF. Lactic acidosis revisited. Diabetes. 1983;32:181–91.
pubmed: 6337898
Kraut JA, Madias NE. Lactic acidosis. N Engl J Med. 2014;371:2309–19.
pubmed: 25494270
Sanivarapu R, Upadrista PK, Otero-Colon J, Shah K, Cadet B, Tao Q, et al. An oncological emergency: severe type B lactic acidosis from Warburg effect in diffuse large B-cell lymphoma. Cureus. 2022;14:e26557.
pubmed: 35936125
pmcid: 9348901
Salcedo Betancourt JD, Garcia Valencia OA, Becerra-Gonzales VG, Carias Martinez KG, Chapman J, Yanchenko N, et al. Severe type-B lactic acidosis in a patient with bilateral renal Burkitt’s lymphoma. Clin Nephrol Case Stud. 2021;9:49–53.
pubmed: 33928009
pmcid: 8079968
Gardner AJ, Griffiths J. A case of type B lactic acidosis as a complication of chronic myelomonocytic leukaemia: a case report and review of the literature. J Med Case Rep. 2015;9:16.
pubmed: 25588681
pmcid: 4325955
Claudino WM, Dias A, Tse W, Sharma VR. Type B lactic acidosis: a rare but life threatening hematologic emergency: a case illustration and brief review. Am J Blood Res. 2015;5:25–9.
pubmed: 26171281
pmcid: 4497494
Friedenberg AS, Brandoff DE, Schiffman FJ. Type B lactic acidosis as a severe metabolic complication in lymphoma and leukemia: a case series from a single institution and literature review. Medicine. 2007;86:225–32.
pubmed: 17632264
Wendon J, Cordoba J, Dhawan A, Larsen FS, Manns M, Nevens F, et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66:1047–81.
pubmed: 28417882
Ferreira FL. Serial evaluation of the SOFA score to predict outcome in critically Ill patients. JAMA. 2001;286:1754.
pubmed: 11594901
Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317:290–300.
pubmed: 28114553
Le Gall J-R. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957.
pubmed: 8254858
Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11.
pubmed: 15384972
Henter J-I, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.
pubmed: 16937360
La Rosée P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133:2465–77.
pubmed: 30992265
Thiéry G, Azoulay E, Darmon M, Ciroldi M, De Miranda S, Lévy V, et al. Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol. 2005;23:4406–13.
pubmed: 15994150
Hourmant Y, Kouatchet A, López R, Mokart D, Pène F, Mayaux J, et al. Impact of early ICU admission for critically ill cancer patients: post-hoc analysis of a prospective multicenter multinational dataset. J Crit Care. 2021;62:6–11.
pubmed: 33227593
Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323:2417.
pubmed: 32369102
Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol. 2019;188:250–7.
pubmed: 30189042
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424.
pubmed: 21818162
pmcid: 3144483
Kliebhan J, Besse A, Kampa-Schittenhelm K, Schittenhelm M, Driessen C. Mutant TP53 driving the Warburg effect in mantle cell lymphoma. Clin Case Rep. 2022;10:e6296.
pubmed: 36225622
pmcid: 9529752
Buppajarntham S, Junpaparp P, Kue-A-Pai P. Warburg effect associated with transformed lymphoplasmacytic lymphoma to diffuse large B-cell lymphoma. Am J Emerg Med. 2013;31:999.e5-6.
pubmed: 23478115
Mayer A, Vaupel P. Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? In: Van Huffel S, Naulaers G, Caicedo A, Bruley DF, Harrison DK, editors. Oxygen transport to tissue XXXV. New York: Springer; 2013. p. 203–9.
San-Millán I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis. 2017;38:119–33.
pubmed: 27993896
Kato Y, Maeda T, Suzuki A, Baba Y. Cancer metabolism: new insights into classic characteristics. Jpn Dent Sci Rev. 2018;54:8–21.
pubmed: 29628997
Vaupel P, Multhoff G. Hypoxia-/HIF-1α-driven factors of the tumor microenvironment impeding antitumor immune responses and promoting malignant progression. In: Thews O, LaManna JC, Harrison DK, editors. Oxygen transport to tissue XL. Cham: Springer International Publishing; 2018. p. 171–5. https://doi.org/10.1007/978-3-319-91287-5_27 .
doi: 10.1007/978-3-319-91287-5_27
Brown TP, Ganapathy V. Lactate/GPR81 signaling and proton motive force in cancer: Role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther. 2020;206:107451.
pubmed: 31836453
Parks SK, Chiche J, Pouysségur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer. 2013;13:611–23.
pubmed: 23969692
Prikis M, Bhasin V, Young MP, Gennari FJ, Rimmer JM. Sustained low-efficiency dialysis as a treatment modality in a patient with lymphoma-associated lactic acidosis. Nephrol Dial Transplant. 2007;22:2383–5.
pubmed: 17510092
Hamaguchi R, Isowa M, Narui R, Morikawa H, Wada H. Clinical review of alkalization therapy in cancer treatment. Front Oncol. 2022;12:1003588.
pubmed: 36185175
pmcid: 9516301
Coiffier B, Altman A, Pui C-H, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. JCO. 2008;26:2767–78.
Ullah MS, Davies AJ, Halestrap AP. The Plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J Biol Chem. 2006;281:9030–7.
pubmed: 16452478
Parks SK, Chiche J, Pouyssegur J. pH control mechanisms of tumor survival and growth. J Cell Physiol. 2011;226:299–308.
pubmed: 20857482
Pouysségur J, Franchi A, Pagès G. pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. In: Goode JA, Chadwick DJ, editors. The tumour microenvironment: causes and consequences of hypoxia and acidity. Hoboken: John Wiley & Sons, Ltd; 2001. p. 186–98. https://doi.org/10.1002/0470868716.ch13 .
doi: 10.1002/0470868716.ch13
Stransky L, Cotter K, Forgac M. The function of V-ATPases in cancer. Physiol Rev. 2016;96:1071–91.
pubmed: 27335445
pmcid: 4982037
Becker HM, Deitmer JW. Proton transport in cancer cells: the role of carbonic anhydrases. Int J Mol Sci. 2021;22:3171.
pubmed: 33804674
pmcid: 8003680
Dean RK, Subedi R, Gill D, Nat A. Consideration of alternative causes of lactic acidosis: thiamine deficiency in malignancy. Am J Emerg Med. 2017;35:1214.e5-1214.e6.
pubmed: 28539246
Shah S, Wald E. Type b lactic acidosis secondary to thiamine deficiency in a child with malignancy. Pediatrics. 2015;135:e221–4.
pubmed: 25548327
Diedrich JD, Rajagurubandara E, Herroon MK, Mahapatra G, Hüttemann M, Podgorski I. Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation. Oncotarget. 2016;7:64854–77.
pubmed: 27588494
pmcid: 5323121
Shen Y, Zhao S, Wang S, Pan X, Zhang Y, Xu J, et al. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma. EBioMedicine. 2019;40:210–23.
pubmed: 30587459
Shen S, Yao T, Xu Y, Zhang D, Fan S, Ma J. CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc. Mol Cancer. 2020;19:151.
pubmed: 33106166
pmcid: 7586679
Elhomsy GC, Eranki V, Albert SG, Fesler MJ, Parker SM, Michael AG, et al. “Hyper-Warburgism”, a cause of asymptomatic hypoglycemia with lactic acidosis in a patient with non-Hodgkin’s lymphoma. J Clin Endocrinol Metab. 2012;97:4311–6.
pubmed: 23055548
Soleja M, Mims M, Rivero G. Uncovering molecular abnormalities leading to the Warburg effect in primary refractory diffuse large B-cell lymphoma. Blood Cancer J. 2016;6:e502–e502.
pubmed: 27911436
pmcid: 5223145
Soga T. Cancer metabolism: key players in metabolic reprogramming. Cancer Sci. 2013;104:275–81.
pubmed: 23279446
pmcid: 7657261
Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais J-P, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119:1901–3.
pubmed: 22215888
pmcid: 3293643
Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15:6479–83.
pubmed: 19861459
pmcid: 2783410
Bunchorntavakul C, Reddy KR. Hepatic manifestations of lymphoproliferative disorders. Clin Liver Dis. 2019;23:293–308.
pubmed: 30947878